Abstract: The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
Abstract: Described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a selective inhibitor of histone deacetylase 8. Also described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a population of autologous T-cells that have been exposed to a selective HDAC8 inhibitor composition ex vivo.
Type:
Application
Filed:
July 18, 2007
Publication date:
May 15, 2008
Applicant:
PHARMACYCLICS, INC.
Inventors:
Joseph J. Buggy, Sriram Balasubramanian
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Type:
Application
Filed:
December 28, 2006
Publication date:
May 8, 2008
Applicant:
PHARMACYCLICS, INC.
Inventors:
Lee Honigberg, Erik Verner, Zhengying Pan
Abstract: The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
Abstract: The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Type:
Application
Filed:
March 28, 2007
Publication date:
March 27, 2008
Applicant:
PHARMACYCLICS, INC.
Inventors:
Lee Honigberg, Erik Verner, Zhengying Pan
Abstract: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.
Type:
Application
Filed:
December 28, 2006
Publication date:
February 14, 2008
Applicant:
PHARMACYCLICS, INC.
Inventors:
Orion Jankowski, James Palmer, Lee Honigberg
Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
Type:
Application
Filed:
August 6, 2007
Publication date:
January 3, 2008
Applicant:
Pharmacyclics, Inc.
Inventors:
Erik Verner, Martin Sendzik, Chitra Baskaran, Joseph Buggy, James Robinson
Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
Type:
Application
Filed:
March 16, 2007
Publication date:
December 6, 2007
Applicant:
PHARMACYCLICS, INC.
Inventors:
Joseph Buggy, Sriram Balasubramanian, Erik Verner, Vincent Tai, Chang-Sun Lee
Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
Type:
Grant
Filed:
April 6, 2004
Date of Patent:
October 2, 2007
Assignee:
Pharmacyclics, Inc.
Inventors:
Eric J. Verner, Martin Sendzik, Chitra Baskaran, Joseph J. Buggy, James Robinson
Abstract: Disclosed herein are novel zinc ionophores, zinc chelators and/or zinc complexes with enhanced aqueous solubility. Methods of treating cancer using at least one zinc ionophore and/or zinc chelator are also disclosed. Also disclosed herein are compositions and methods for treating cancer with combination therapy using at least one texaphyrin metal complex and at least one zinc ionophore or the respective pharmaceutically acceptable derivatives or salts thereof.
Abstract: Described herein are methods of treating cancer by administering a therapeutically effective amount of at least one texaphyrin metal complex or a pharmaceutically acceptable derivative, and performing stereotactic radiosurgery to the patient. In some embodiments, at least one texaphyrin metal complex or a pharmaceutically acceptable derivative is administered while the patient is undergoing a radiation therapy. Also described herein are methods for detecting various cancerous tumors, lesions, or metastases in a patient by administering an effective amount of at least one texaphyrin metal complex or a pharmaceutically acceptable derivative before a patient undergoes stereotactic radiosurgery. Also described herein are methods for visualizing tumors not otherwise visualized; methods for detecting the margins of a tumor; and methods for improving the targeting of the SRS radiation.
Abstract: The present invention is directed to the mesylate salt of 5-(2-dimethylamino-ethoxy)-1H-indole-2-carboxylic acid [3-(4-hydroxycarbamoylphenyl)prop-2-ynyl]amide, pharmaceutical compositions and processes for preparing the same.
Abstract: A packaging system is described for a drug that provides protection from contamination, crystallization and/or degradation of the drug during storage of the system prior to its use. The packaging of the drug does not significantly absorb, react with, or otherwise adversely affect the therapeutic effectiveness of the drug or other excipients or components during storage of the system prior to its use. The packaging system is also used for preserving a drug, particularly a drug containing high-purity texaphyrin metal complexes, by providing a product packaging system that prevents, limits or otherwise controls degradation reactions that can result from exposure to oxygen and/or light.
Type:
Application
Filed:
September 30, 2005
Publication date:
April 5, 2007
Applicant:
Pharmacyclics, Inc.
Inventors:
Norbert Purro, Hugo Madden, Suzanne Nguyen
Abstract: Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed.
Type:
Grant
Filed:
January 7, 2005
Date of Patent:
January 9, 2007
Assignee:
Pharmacyclics, Inc.
Inventors:
Darren Magda, Dale Miles, Nikolay Gerasimchuk, Cheryl Lepp
Abstract: Compounds, pharmaceutical formulations and methods for use in neutron capture therapy are provided, useful for treating diseases characterized by neoplastic tissue and arteriosclerosis.
Type:
Application
Filed:
May 19, 2005
Publication date:
December 28, 2006
Applicant:
Pharmacyclics, Inc.
Inventors:
Tarak Mody, Jonathan Sessler, Stuart Young
Abstract: The present invention provides certain non-symmetric tripyrranes; that is, tripyrranes that do not contain a mirror plane of symmetry perpendicular to the plane containing the tripyrrane. Further, the invention includes texaphyrin compounds and sapphyrin compounds, as well as other polypyrrolic macrocycles, prepared using tripyrranes of Formula I as a precursor. These macrocycles are characterized by a tripyrrolic portion of the macrocyclic ring having substituents that cause the heterocycle to lack a plane of symmetry perpendicular to the plane of the macrocycle.
Abstract: Embodiments of the present invention comprise computer-based tools facilitating visualization and assessment of progression of neurological disorders in a patient. In one embodiment, data is received in the form of the results of standardized neurological examination of the patient. This input is compared to a rule set defining progression of the disorder, and the results of this comparison are displayed in an electronic document featuring internal links. The data may be displayed as tables and/or charts, with elapsed time plotted along a row/column or axis, respectively. Progression indication may be displayed through changed color. The electronic document can also display data not directly relevant to neurological condition, for example medication and radiation treatment schedules. By automatically displaying the data and the derived progression assessment according to the rule set, embodiments of the present invention are of particularly use in rapidly and uniformly evaluating treatment therapies.
Type:
Application
Filed:
December 20, 2005
Publication date:
June 22, 2006
Applicant:
Pharmacyclics, Inc.
Inventors:
Brad Harris, Jennifer Smith, See-Chun Phan
Abstract: The present invention relates to novel compositions comprising, (i) at least one of Taxol, Taxotere, bleomycin, carmustine, carboplatin, and doxorubicin; and (ii) MGd, a compound of Formula I. The present invention also relates to and methods of using said compositions to treat Cancer.